Telitacicept for Injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Medicine type
- Biologic
- Therapeutic area
- Immunology & rheumatology
- Indications recorded in the public source
- Systemic lupus erythematosus (SLE): in combination with standard therapy, for adults with active, autoantibody-positive SLE and persistently high disease activity despite standard therapy (for example, positive anti-dsDNA antibodies with low complement and a SELENA-SLEDAI score of at least 8). Rheumatoid arthritis: in combination with methotrexate, for adults with moderate-to-severe active rheumatoid arthritis with an inadequate response to methotrexate. Generalized myasthenia gravis (gMG): in combination with standard treatments, for adults with anti-acetylcholine receptor (AChR) antibody-positive gMG.
- Indication source and scope
- Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- Prescribing-information limitations
- Indications checked against an official public submission. The full original prescribing information is still unavailable.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Limited to: (1) adults with active, autoantibody-positive SLE and persistently high disease activity despite standard therapy (for example, positive anti-dsDNA antibodies with low complement and a SELENA-SLEDAI score of at least 8); (2) adults with anti-AChR antibody-positive generalized myasthenia gravis (gMG).
- Insurance period
- 2026-01-01 to 2027-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.cnpharm.com/c/2022-06-01/827272.shtml
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.nhsa.gov.cn/attach/Ypsn2025/YPSN202500169/YPSN202500169.pdf
Open the interactive record, public price references and discussions